Recent studies show that popular weight loss drugs like Ozempic may reduce the risk of developing colon cancer. So how does this process work?
Elchi.az reports that the age group of colon cancer cases is getting younger every day. The disease is more common especially in young people in their late 20s. Since symptoms are not detected in the early stages, the chance of treatment decreases, which increases the risk of death. However, recent studies show that popular weight loss drugs like Ozempic may reduce the risk of developing colon cancer.
According to a statement at the American Clinical Oncology Society’s 2026 symposium, GLP-1 drugs are more effective than aspirin in preventing colorectal cancer.
In addition, people taking GLP-1 drugs are less likely to experience side effects such as kidney damage, stomach ulcers, or gastrointestinal bleeding compared to those taking aspirin.
The potential of low-dose aspirin to prevent colorectal cancer has been known for years. Aspirin, which stands out with its anti-inflammatory effect, also prevents the growth of precancerous polyps in the colon. However, it also carries significant risks such as gastrointestinal bleeding and cerebral hemorrhage.
A study of more than 280,000 people found that those taking Ozempic or Wegovy were 26 percent less likely to develop cancer compared to those taking aspirin.
This is not the only benefit of GLP-1 drugs. In addition to lowering blood sugar, GLP-1 reduces systemic inflammation and increases insulin sensitivity. All these changes inhibit cancer growth.
There are 13 types of cancer known to be associated with obesity. These include breast, stomach, colon and prostate cancers.
Experts claim that Ozempic can combat the risk of cancer because it slows down weight gain.
However, it is emphasized that more research is needed on this topic.
Şayəstə